×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
ON DEMAND - Regulatory Barriers to Entry for Biosimilars
Session Chair(s)
Rachel Turow, JD, MPH
Managing Counsel, FDA Regulatory
Walmart, Inc., United States
FDA is making important strides in reviewing and approving biosimilars. But, there are still some limitations to the program under BsUFA II that are interfering with biosimilar sponsors' ability to access the market.
Learning Objective : Discuss how the regulatory process for biosimilars is hindering their uptake in the marketplace; Describe how the FDA can improve the regulatory process for biosimilars to encourage and improve market uptake.
Speaker(s)
Industry Update
Leah Christl, PhD
Amgen, United States
Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy
FDA Update
Eva Temkin, JD
King & Spalding LLP, United States
Partner, FDA and Life Sciences
Moderator
Julie Anne Zawisza, MA, MT
Merck & Co., Inc., United States
Senior Director, Global Regulatory Policy, MRL GRACS
Have an account?